[CEMI] Chembio Diagnostics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 6.75 Change: 0.15 (2.27%)
Ext. hours: Change: 0 (0%)

chart CEMI

Refresh chart

Strongest Trends Summary For CEMI

CEMI is in the medium-term down -18% below S&P in 4 months. In the long-term down -36% below S&P in 1 year and up 305% in 16 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company?s products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a Syphilis multiplex test for the detection of antibodies to HIV and Syphilis; and a rapid test for the detection of Hepatitis-C antibodies and antigens. Chembio Diagnostics, Inc. sells its products under STAT PAK, SURE CHECK, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with th

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.39 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -16.06% Sales Growth - Q/Q-12.18% P/E-4.32
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-6.48% ROE-8.13% ROI
Current Ratio3.32 Quick Ratio2.56 Long Term Debt/Equity Debt Ratio0.25
Gross Margin40.01% Operating Margin-7.28% Net Profit Margin-5.56% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-860 K Cash From Operating Activities-940 K Gross Profit2.69 M
Net Profit-650 K Operating Profit-880 K Total Assets24.07 M Total Current Assets16.2 M
Total Current Liabilities4.89 M Total Debt Total Liabilities4.89 M Total Revenue6.23 M
Technical Data
High 52 week11.5 Low 52 week4.95 Last close5.99 Last change-0.17%
RSI47.25 Average true range0.32 Beta0.29 Volume9.76 K
Simple moving average 20 days0.82% Simple moving average 50 days-0.86% Simple moving average 200 days-7.7%
Performance Data
Performance Week-0.5% Performance Month0% Performance Quart-21.9% Performance Half-11.91%
Performance Year-47.69% Performance Year-to-date5.83% Volatility daily3.13% Volatility weekly7%
Volatility monthly14.35% Volatility yearly49.71% Relative Volume90.03% Average Volume34.39 K
New High New Low

News

2019-09-13 08:18:22 | Chembio Diagnostics NASDAQ:CEMI Has Debt But No Earnings; Should You Worry?

2019-09-04 08:00:00 | Chembio Diagnostics Announces $20 Million Term Loan with Perceptive Advisors

2019-08-27 16:05:00 | Chembio Diagnostics to Participate in Upcoming Investor Conferences

2019-08-14 11:28:46 | What Kind Of Shareholder Owns Most Chembio Diagnostics, Inc. NASDAQ:CEMI Stock?

2019-08-09 13:34:56 | Edited Transcript of CEMI earnings conference call or presentation 6-Aug-19 8:30pm GMT

2019-08-06 16:05:00 | Chembio Diagnostics Reports Second Quarter 2019 Financial Results

2019-07-24 16:05:00 | Chembio Diagnostics to Participate in the Canaccord Genuity Growth Conference

2019-07-24 08:00:00 | Chembio Diagnostics to Report Second Quarter 2019 Financial Results on August 6, 2019

2019-07-18 08:00:00 | Chembio Diagnostics and Takeda Pharmaceutical Company Enter Collaboration to Develop Point-of-Care Diagnostic Test

2019-07-15 13:43:42 | Should You Be Concerned About Chembio Diagnostics, Inc.'s NASDAQ:CEMI Historical Volatility?

2019-06-27 09:27:57 | Chembio Diagnostics Receives CE Mark for its Point-of-Care Multiplex Test for Zika, Dengue and Chikungunya

2019-05-07 08:00:00 | Chembio Diagnostics Announces Approval of Dengue Point-of-Care Test by Brazil’s Health Regulatory Agency

2019-05-02 03:31:26 | Edited Transcript of CEMI earnings conference call or presentation 1-May-19 8:30pm GMT

2019-05-01 16:05:00 | Chembio Diagnostics Reports First Quarter 2019 Financial Results

2019-04-29 10:44:11 | Introducing Chembio Diagnostics NASDAQ:CEMI, The Stock That Zoomed 142% In The Last Five Years

2019-04-22 17:11:45 | Chembio Diagnostics to Report First Quarter 2019 Financial Results on May 1, 2019

2019-04-09 08:02:00 | Chembio Diagnostics Announces Approval of Zika, Dengue and Chikungunya Point-of-Care Multiplex Test by Brazil’s Health Regulatory Agency

2019-04-02 08:00:00 | Chembio Diagnostics Announces Agreement with Perseus Science to Advance Point-of-Care Concussion Test

2019-03-18 10:00:00 | CEMI: Revenue, margin guidance and historical context indicates this could be opportune entry point

2019-03-18 08:48:02 | Chembio Diagnostics Inc CEMI Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-11 14:26:31 | Have Insiders Been Buying Chembio Diagnostics, Inc. NASDAQ:CEMI Shares?

2019-03-07 20:40:18 | Edited Transcript of CEMI earnings conference call or presentation 7-Mar-19 9:30pm GMT

2019-03-07 17:00:37 | Chembio Diagnostics Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-07 16:02:00 | Chembio Diagnostics Awarded UNICEF Contract to Supply Point-of-Care Zika/Chikungunya/Dengue Tests and Micro Readers

2019-02-25 08:30:00 | Chembio Diagnostics to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

2019-02-19 18:17:20 | Chembio Diagnostics to Participate in the BTIG Medical Technology, Life Science and Diagnostic Tools Conference

2019-02-07 08:20:40 | Do Insiders Own Shares In Chembio Diagnostics, Inc. NASDAQ:CEMI?

2019-02-06 07:30:00 | Chembio Diagnostics Reports Preliminary Fourth Quarter and Full Year 2018 Revenue

2019-01-17 16:10:00 | Chembio Diagnostics Announces 2019 Analyst and Investor Meeting

2019-01-07 07:00:00 | Chembio Diagnostics Receives CE Mark for Point-of-Care Diagnostic Test  Developed in Collaboration with AstraZeneca

2019-01-01 14:49:40 | Chembio Diagnostics, Inc.’s NASDAQ:CEMI Path To Profitability

2018-12-06 08:00:00 | Chembio’s French Partner AAZ-LMB Wins Prix Galien International for Best Medical Technology with autotest VIH®

2018-11-29 16:30:00 | CEMI: Record YTD Revenue, Margin Improvement Should Soon Follow

2018-11-13 08:20:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Sun Hydraulics, FIS, TRACON Pharmaceuticals, Kona Grill, Endava PLC Sponsored ADR, and Chembio Diagnostics — New Research Emphasizes Economic Growth

2018-11-09 11:14:01 | Chembio Ebola Virus Diagnostic Test Receives U.S. FDA Emergency Use Authorization

2018-11-09 09:27:55 | Edited Transcript of CEMI earnings conference call or presentation 8-Nov-18 9:30pm GMT

2018-11-09 08:00:00 | Chembio to Participate in Upcoming Investor Conferences

2018-11-08 16:18:30 | Chembio Diagnostics Reports Third Quarter 2018 Financial Results

2018-11-01 07:00:00 | Chembio Diagnostics Announces Pricing of its Public Offering of Common Stock

2018-10-31 16:05:00 | Chembio Diagnostics Announces Proposed Public Offering of Common Stock

2018-10-31 08:00:00 | Chembio to Report Third Quarter 2018 Financial Results on November 8, 2018

2018-10-25 08:00:00 | Chembio Determines Not to Proceed with Proposed Public Offering of Common Stock

2018-10-22 17:27:17 | Chembio Announces Proposed Public Offering of Common Stock

2018-10-22 16:38:39 | Chembio Reports Preliminary Third Quarter 2018 Revenue

2018-10-17 07:00:00 | EXPLAINER-Why it’s so hard to diagnose Zika

2018-10-17 01:00:00 | EXPLAINER-Why it’s so hard to diagnose Zika

2018-10-16 07:00:00 | Chembio Receives $10.5 Million Commitment from Bio-Manguinhos for Production of DPP® Assays in Brazil

2018-09-19 09:47:42 | Is Chembio Diagnostics Inc NASDAQ:CEMI A Cash Cow?

2018-08-22 21:55:51 | Edited Transcript of CEMI earnings conference call or presentation 8-Aug-18 8:30pm GMT

2018-08-20 12:45:00 | CEMI: Ethiopian Tender, Bio-Manguinhos Order Propel Q2 Product Sales. More Revenue Catalysts Emerge.